Both are intended to increase the anti-cancer efficacy and reduce the toxicity by slow conversion of the drug to fluorouracil through the cytochrome P-450 metabolic pathway [16] in the former and by dominant delivery of fluorouracil in cancer tissues in the latter [12]. This evidence concerns the gene CYP4F3 and cancer.